BridgeBio Oncology Therapeutics Inc.
BBOT
Get informed when a big investor buys or sells
+ FollowMarket Cap$214.55K
Close$
Share Statistics
| Market cap | $214,545.00 |
|---|---|
| Enterprise Value | $-51,334,455.00 |
| Dividend Yield | $- (-) |
| Earnings per Share | $-4.3 |
| Beta | 0.39 |
| Outstanding Shares | 80,054 |
Return
| Return on Equity | -72.12% |
|---|---|
| Return on Assets | -61.86% |
| Return on Invested Capital | -61.33% |
Valuation & Multiples
| P/E Ratio | 0 |
|---|---|
| PEG | -0.25 |
| Price to Sales | - |
| Price to Book Ratio | 0.0 |
| Enterprise Value to Revenue | - |
| Enterprise Value to EBIT | -1.07 |
| Enterprise Value to Net Income | 0 |
| Total Debt to Enterprise | 0.01 |
| Debt to Equity | 0.01 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 11, 2026
EPS Estimate
$-0.56
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationNext Earnings Call
Expected Date
November 11, 2026
EPS Estimate
$-0.69
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 74219.11%▲ 2453.84% |
|---|---|
| Total Invested | $452.77M▼ 11.88% |
| Investors Holding | 670% |
ESG Score
No data
About Helix Acquisition Corp. II
88 employees
CEO: Pedro J. Beltran BridgeBio Oncology Therapeutics, Inc., a clinical-stage biotechnology company, engages in the development of small-molecule therapeutics for the treatment of renin-angiotensin system and phosphoinositide 3-kinase malignancies in the Unit...